CAR T-Cell Therapy Treatment for Lymphoma - Update
by Dr. C.H. Weaver M.D. updated 7/2020
The US Food and Drug Administration (FDA) has approved three chimeric antigen receptor (CAR) technologies for the treatment of malignant lymphoma. Yescarta (Axicabtagene ciloleucel) and Kymriah (tisagenlecleucel-T) were the first CAR therapies to be approved. Tecartus™ (brexucabtagene autoleucel, formerly KTE-X19) was approved in July 2020 for the treatment of advanced Mantle Cell Lymphoma Second-generation CAR T cellular immunotherapy products are being developed to overcome resistance, reduce side effects and simplify treatment. Both allogenic umbilical cord blood derived CAR T cells and FT596 appear very promising.
CAR therapies utilize T-cells (CART T), a patient’s own immune cells that are re-programmed to recognize and kill cancer cells throughout the body. The process involves the removal of some T cells from a patient, and through laboratory processes, these T cells are re-programmed to identify a patient’s cancer cells.
Once the T cells have been programmed to identify a patient’s cancer cells, they are replicated in the laboratory, and infused back into the patient. These re-programmed T cells circulate throughout the body, identifying the cancer cells and mounting an immune attack against them. Simultaneously, the T cells are replicating within the body, so that more of the immune cells can identify and attack the cancer cells.
Long-Term Outcomes of Yescarta
The ZUMA-1 clinical trial enrolled 119 adults with relapsed or refractory large B-cell lymphoma to receive treatment with a chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of Yescarta.
In the ZUMA-1 clinical trial, Yescarta showed durable responses and no new safety concerns in patients with relapsed or refractory large B-cell lymphoma according to 2-year follow-up data published in Lancet Oncology. (2,5)
Overall 83% of treated patients responded to treatment and 58% had a complete response. Thirty-nine patients (39%) had an investigator-assessed ongoing response, with a median duration of response of 11.1 months. The median overall survival was not yet reached.
Fifty patients died from progressive lymphoma while on study, with 6 deaths occurring during the first year follow-up analysis. Four patient deaths were related to adverse events, 2 of which were related to treatment with Yescarta.
With a minimum follow-up of three years after a single infusion of Yescarta (median follow-up of 39.1 months), 47% of patients with refractory large B-cell lymphoma in the ZUMA-1 clinical survive, and the median overall survival was 25.8 months.
KTE - C19
Kite Pharma reported on 51 patients with advanced diffuse large B-cell lymphoma (DLBCL) who were treated with Kite’s KTE-C19. Initially, 76% of the patients responded to treatment, 47% of patients went into complete remission. By comparison, similar DLBCL patients treated again with chemotherapy in previous studies only achieve an 8%-10% complete response rate. Two lymphoma patients in the study died due to treatment with KTE-C19, the company said. Serious neurological toxicity was reported in 34% of patients.Another trial evaluating the effectiveness of CAR T cell therapy included 22 patients with different types of advanced B-cell lymphomas that had progressed following prior therapies. All patients received chemotherapy prior to a single infusion of the CAR T cells.
- Of 19 patients who had different subtypes of diffuse large B-cell lymphoma (DLBCL), 8 achieved a complete disappearance of their cancer; 5 achieved a partial disappearance of their cancer; 2 achieved disease stabilization; and 4 experienced a progression of their disease.
- Of the 2 patients with follicular lymphoma, and the single patient with mantle cell lymphoma, all achieved a complete disappearance of their cancer.
- Two patients with refractory chronic lymphocytic leukemia are reported to be in complete remission for 8 years as of May 2019.
Mantle Cell Lymphoma
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Tecartus™ (brexucabtagene autoleucel, formerly KTE-X19), chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). The approval is based on results of the ZUMA-2 clinical trial in which 87 percent of patients responded to a single infusion of Tecartus, including 62 percent of patients achieving a complete response (CR). (14)
In the trial, 18 percent of patients (n=82 evaluable for safety) experienced Grade 3 or higher CRS and 37 percent experienced neurologic events. The most common (≥ 10 percent) Grade 3 or higher adverse reactions were anemia, neutropenia, thrombocytopenia, hypotension, hypophosphatemia, encephalopathy, leukopenia, hypoxia, pyrexia, hyponatremia, hypertension, infection-pathogen unspecified, pneumonia, hypocalcemia and lymphopenia.
It had been previously reported that 92% of patients with relapsed/refractory MCL responded to treatment with KTE-X19 in the the ZUMA-2 trial presented at the 2019 ASH Annual Meeting. The ZUMA-2 clinical trial treated 74 patients with relapsed/refractory MCL who had received up to five prior lines of therapy, including an anti-CD20 antibody, chemotherapy, and a BTK inhibitor with a single infusion of KTE-X19 at a target dose of 2×106 CAR T cells/kg.(10)
Findings for the first 60 treated patients with a median follow-up of 12.3 months were reported at ASH 2019.
- 93% overall response rate - 67% complete response.
- One-year overall survival of 83%.
- Cytokine release syndrome (CRS) in 91% a median of two days after KTE-X19 administration – all resolved.
CAR T cell therapy appears to be a promising new treatment option for individuals with relapsed or recurrent MCL which led to the FDA approval for Mantle Cell lymphoma. Greater clarity is also being provided regarding two significant side effects associated with CAR T cell therapy.
- Cytokine Release Syndrome (CRS): CRS occurred in 94% of patients with a median time to onset of 2 days (range: 1-12 days) and a median duration of 7 days (range: 2-58 days). Key manifestations of CRS include fever (78%), hypotension (41%), tachycardia (28%), hypoxia (22%), and chills (20%). At the first sign of CRS physicians now institute treatment with tocilizumab and/or corticosteroids.
- Neurologic side effects: Neurologic side effects are reported to occur in 87% of patients, all occurring within the first 8 weeks of therapy. The most common include encephalopathy (57%), headache (44%), tremor (31%), dizziness (21%), aphasia (18%), delirium (17%), insomnia (9%) and anxiety (9%). Prolonged encephalopathy lasting up to 173 days was noted. Serious events including leukoencephalopathy and seizures occurred with Yescarta®. Fatal and serious cases of cerebral edema have occurred in patients treated with Yescarta®.
While the initial FDA approval is for "transplant ineligible patients" there is of course great hope that CAR T cell therapy will also improve the outcomes compared with stem cell transplant used earlier in the disease course. It is of interest that the treatment related mortality from CAR T of ~ 4% and the 3 year disease free survival are similar to that obtained with a standard stem cell transplant. Moreover the neurologic side effects and CRS are not insignificant. Comparative clinical trials may be necessary to determine how the side effects compare to a standard stem cell transplant and whether the additional cost for CAR-T cell therapy is warranted.
Advances in CD19‐targeted CAR T‐cell therapies have led to a new standard of care for heavily pretreated relapsed/relapsed diffuse large B‐cell lymphoma (DLBCL). Despite the clinical benefits of CAR T‐therapy, only 29% to 37% of patients with relapsed/refractory DLBCL achieved a durable complete response. (2,11)
Several potential mechanisms of resistance to CD19‐directed CAR T‐cell therapy have been proposed, including CD19 antigen loss and programmed death‐ligand 1 (PD‐L1) upregulation, leading to CAR T‐cell exhaustion. (12,13) Strategies to overcome these resistance mechanisms include the simultaneous targeting of both CD19 and CD22 to reduce the probability of antigen loss, as well as the use of a checkpoint inhibitor to prevent PD‐L1‐mediated CAR T‐cell exhaustion.
- Keep Current With The Lymphoma Newsletter
- Connect With Others In The Lymphoma Community To Share Information And Support
New Approaches Aim to Enhance CAR T-Cell Therapy
CAR T cell therapies are developed by collecting a patient’s own T cells and engineering them to target proteins specific to the surface of their cancer cells and reintroducing these modified T cells back into the patient’s immune system to kill the cancer cells. First-generation CAR T-cell therapies primarily target CD-19, a protein found on the surface of most normal and malignant B cells in B cell cancers such as lymphoma. Current CAR T-cell therapies need to become more effective, more affordable and safer. The results of early-phase clinical studies of “second-generation” CAR T cellular immunotherapy products may overcome resistance, reduce side effects and simplify treatment.
CD19 /CD22 Dual‐Targeted CAR‐T Therapy
AUTO3 is an investigational CAR T‐cell therapy targeting both the CD19 and CD22 antigens on lymphoma cells and shows promise when combined with Keytruda (pembrolizumab) immunotherapy in patients with relapsed/refractory diffuse large B‐cell lymphoma (DLBCL), according to results from the Alexander phase I clinical trial released at the 2020 American Society of Clinical Oncology Annual meeting.
AUTO3 delivers two CARs targeting CD19 and CD22, respectively, in a single retroviral vector. The phase I/II Alexander clinical trial was designed to evaluate the safety and effectiveness of AUTO3 in combination with the checkpoint inhibitor Keytruda (pembrolizumab) in patients with relapsed/refractory DLBCL.
A preliminary report on the first 23 patients demonstrated that 65% of patients with relapsed/refractory DLBCL responded to treatment and no cases of severe cytokine release syndrome were observed - one patient developed grade 3 neurotoxicity. The patient was treated with steroids, and symptoms improved in 3 days. These preliminary findings suggest that a dual‐targeted anti‐CD19/CD22 CAR T‐cell therapy is safe and effective for patients with relapsed/refractory DLBCL. (9,10)
Allogeneic CAR T Cell Therapy
Allogeneic derived chimeric antigen receptor (CAR) cell meaning the cells were taken from a non-related healthy donor rather than the patient themselves may have several advantages including;
- The potential to be manufactured in advance and stored for off-the-shelf immediate use which is in contrast to most available CAR T cells which require the use of a patient’s own genetically modified T cells, created through a multi-week manufacturing process.
- Avoidance of CAR T cell cytokine release syndrome and neurotoxicity.
- Lower cost.
Researchers have used allogenic umbilical cord blood-derived chimeric antigen receptor (CAR) natural killer (NK)-cell therapy targeting CD19 in patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL), with no major side effects observed. Eleven patients participating in the study had NK cells isolated from donated umbilical cord blood and genetically engineered to express the CAR, which recognizes CD19. The CAR NK cells were also ‘armored’ with IL-15, an immune signaling molecule that is designed to enhance expansion and survival of the cells. (6)
Side effects experienced by participants were primarily related to the conditioning chemotherapy given before cell infusion and were resolved within one to two weeks and no patient required admission to an intensive care unit for management of treatment side effects. Seventy-three percent of patients responded to therapy and seven of those achieved a complete response. Responses to the CD19 allogenic CAR NK cell therapy were evident within one month following infusion, and persistence of CAR T cells was confirmed out to one-year post-infusion. Importantly NO patients experienced cytokine release syndrome or neurotoxicity.
Off-the-Shelf CAR NK Products – FT596
Cellular immunotherapy for B cell cancers could ultimately become an off-the-shelf product, capable of being uniformly manufactured in large quantities as prescription drugs are.
A product, dubbed FT596, is among the first cellular immunotherapies to be based on off-the-shelf NK cells – the “first line of defense” of the immune system – and is the first cellular immunotherapy to be genetically engineered to contain three active anti-tumor components
FT596 demonstrated comparable ability to kill cancerous white blood cells as standard CAR T cells and, when combined with the drug Rituxan, killed cancerous white blood cells that were no longer responding to standard CAR T-cell therapy due to loss of the CD19 antigen target.
The U.S. Food and Drug Administration (FDA) approved Fate Therapeutics’ Investigational New Drug Application for FT596 in September 2019 and the first patient was treated in March of 2020.
The process of creating FT596 begins with human induced pluripotent stem cells (iPSCs) that are uniquely capable of unlimited self-renewal and can differentiate into more than 200 types of human cells. The iPSCs are genetically engineered, after which a single clone (genetically engineered cell) is selected and multiplied in the laboratory to create a master engineered cell line that can be repeatedly used to generate cancer-fighting immune-system cells such as NK and T cells.
In addition to engineering FT596 to carry a CAR targeting the CD19 protein – which is produced by nearly all B-cell lymphomas and leukemias researchers inserted two other novel proteins: CD16, which boosts and broadens the NK cells’ ability to kill cancer cells, and IL15, which stimulates FT596 to multiply and survive longer.
FT596 has been designed to address two other limitations of CAR T-cell therapy.
- As an off-the-shelf product the time-consuming and costly process that is currently required to treat a patient with CAR T cells is eliminated.
- The addition of the CD16 protein gives FT596 broader therapeutic activity and versatility. In combination with a drug such as Rituxan, FT596 has the potential to lead to deeper and more durable responses and overcome resistance that hampers the long-term efficacy of CAR T-cell therapy. (7,8)
- Locke FL, Ghobadi A, Jacobson CA, et al. [Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1–2 trial](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18%2930864-7/fulltext). Lancet Oncol. 2019;20(1):31-42.
- Osborne W, Marzolini, Tholouli E et al. Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR T cell therapy, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL. Presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program. May 29–31, 2020. Abstract 8001. Available at
- Schuster SJ, Bishop MR, Tam CS et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B‐cell lymphoma. N Engl J Med 2019; 380: 45– 56.
- Yoon DH, Osborn MJ, Tolar J et al. Incorporation of immune checkpoint blockade into chimeric antigen receptor T cells (CAR‐Ts): Combination or built‐In CAR‐T. Int J Mol Sci 2018; 19: 340.
- Neelapu SS, Locke FL, Bartlett NL et al. Axicabtagene ciloleucel CAR T‐cell therapy in refractory large B‐cell lymphoma. N Engl J Med 2017; 377: 2531– 2544.
FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma
The U.S. Food and Drug Administration today approved Yescarta (axicabtagene ciloleucel), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment. Yescarta, a chimeric antigen receptor (CAR) T cell therapy, is the second gene therapy approved by the FDA and the first for certain types of non-Hodgkin lymphoma (NHL).
Update on CAR T Cell Therapies for the Treatment of Cancer
What you need to know about CAR T cell cancer treatment - New approaches may reduce costs and side effects.
Kite Announces Long-term Data From ZUMA-1 Showing Approximately Half of Refractory Large B-cell Lymphoma Patients Were Alive Three Years After Yescarta…
The Investor Relations website contains information about Gilead Sciences's business for stockholders, potential investors, and financial analysts.
FT596 - Fate Therapeutics
T cells engineered with chimeric antigen receptors (CARs) have shown exceptional promise as a potentially curative therapy for patients with certain hematologic malignancies. While most researchers and clinical investigators continue to focus on the development of autologous or allogeneic CAR T-cell therapies, we are developing CAR NK cell product candidates created from clonal master engineered […]
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma | NEJM
Abstract Background Patients with relapsed or refractory mantle-cell lymphoma who have disease progression during or after the receipt of Bruton’s tyrosine kinase (BTK) inhibitor therapy have a poo...
CD19/CD22 Dual‐Targeted CAR‐T Therapy Active in Relapsed/Refractory DLBCL
AUTO3, the first chimeric antigen receptor (CAR) T‐cell therapy targeting both CD19 and CD22, shows promise in combination with pembrolizumab in patients with relapsed/refractory diffuse large B‐ce...
Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR T cell therapy, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL.
8001Background: CD19 directed CAR T cells are effective in patients with r/r DLBCL, however relapses due to CD19 loss or PDL1 upregulation are common. In this study, we evaluate the safety and effi...
U.S. FDA Approves Kite’s Tecartus™, the First and Only CAR T Treatment for Relapsed or Refractory Mantle Cell Lymphoma | Gilead Sciences
The Investor Relations website contains information about Gilead Sciences's business for stockholders, potential investors, and financial analysts.
Copyright © 2018 CancerConnect. All Rights Reserved.